<p>TransCode Therapeutics Inc. has filed Amendment No. 2 to its Current Report on Form 8-K to report the effective date of its Contingent Value Rights (CVR) Agreement and to note a change in the rights agent. The executed CVR Agreement with Vstock Transfer, LLC is included as an exhibit in the filing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-100456), on October 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

RNAZ

<p>TransCode Therapeutics Inc. has filed Amendment No. 2 to its Current Report on Form 8-K, reporting the effective date of its Contingent Value Rights (CVR) Agreement and a change in the rights agent. The CVR Agreement with Vstock Transfer, LLC is included as an exhibit in the filing.</p>

TransCode Therapeutics Updates SEC Filing to Report CVR Agreement Effective Date and Change in Rights Agent